Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of gemcitabine + EndoTAG-1 (lipid-complexed paclitaxel) vs gemcitabine in locally advanced/metastatic pancreatic adenocarcinoma
2005-000666-39Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Oct 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of EndoTAG-1 in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Medigene AG. Primary endpoint: Efficacy Endpoints. Started Oct 2005; status: completed.
02
Drugs
EndoTAG-1
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2005-000666-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000666-39.